CryoPort Inc ( (CYRX) ) has released its Q1 earnings. Here is a breakdown of the information CryoPort Inc presented to its investors.
Cryoport, Inc. is a global leader in temperature-controlled supply chain solutions for the life sciences sector, focusing on regenerative medicine and supporting biopharmaceutical companies with a comprehensive suite of services and products.
Cryoport reported a strong start to 2025, with first-quarter revenue from continuing operations reaching $41.0 million, marking a 10% increase year-over-year. The company also highlighted a significant 33% revenue growth in its commercial Cell & Gene therapy segment and announced a strategic partnership with DHL, which is expected to enhance its operational reach.
The company’s Life Sciences Services revenue increased by 17% year-over-year, driven by the growing development and commercialization of Cell & Gene-based therapies. Cryoport’s gross margin improved to 45.4%, up from 40.4% the previous year, while operating costs decreased by 13.7%. The company also reported a reduced net loss of $12.0 million compared to $18.9 million in the same quarter last year, with adjusted EBITDA showing improvement.
Cryoport’s strategic partnership with DHL is anticipated to provide a strong infusion of capital and enhance its competitive profile, particularly in the APAC and EMEA regions. The company remains focused on supporting the rollout of commercial regenerative medicine products globally and is advancing initiatives such as its IntegriCell™ Cryopreservation Solution and new product introductions.
Looking ahead, Cryoport maintains an optimistic outlook for the remainder of 2025, reiterating its revenue guidance of $165.0 million to $172.0 million for the fiscal year. The company expects to continue benefiting from its strategic initiatives and partnerships, positioning itself for sustained growth in the life sciences sector.